Skip to main content
Equibles
BCRX logo

BCRX · Biocryst Pharmaceuticals Inc · Metrics

Track BCRX — free

Use BCRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BCRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$7.69 +0.06 (+0.79%) At close · Nov 6 Play latest call Q3 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$1.98B
Shares
257.30M
Volume · Nov 6 5.21M Avg daily vol (3M) 4.93M

BCRX metrics

93 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$7.69
Market cap
$1.98B

Price action

23 metrics
Price change (1W)
-9.2%
Price change (30D)
-7.2%
Price change (3M)
-18.0%
Price change (6M)
-10.8%
Price change (YTD)
-1.4%
Price change (1Y)
+9.4%
Trailing year
Price change (5Y)
-38.0%
52-week high
$11.11
52-week low
$6.24
Change from 52-week high
-30.8%
Change from 52-week low
+23.2%
Annualized volatility
48.2%
Annualized volatility (3M)
47.2%
Implied volatility (30D)
55.3%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
0.7
RSI (14D)
40.8
Price vs SMA 50
-9.1%
Price vs SMA 200
-12.4%
Avg volume (3M)
4.93M
Relative volume
1.1
Average dollar volume
$42.22M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
257.30M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
2.1×
reciprocal yield 48.1%
EV / EBITDA
5.0×
reciprocal yield 20.1%
EV / EBIT
—
P / sales
2.1×
reciprocal yield 48.6%
P / book
—
FCF yield
18.5%
TTM · current market cap
Buyback yield
0.0%
P / FCF
5.4
reciprocal yield 18.5%
P / operating cash flow
5.4
reciprocal yield 18.6%
Earnings yield
-18.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
28.1×
reciprocal yield 3.6%
EV / revenue historical average (5Y)
28.1×
reciprocal yield 3.6%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-04

Profitability

9 metrics
Gross margin
97.9%
Operating margin
-30.1%
Trailing 12 months
Net margin
-37.4%
Gross profit (TTM)
$941.20M
Operating profit (TTM)
−$289.42M
Net income (TTM)
−$359.66M
Trailing 12 months
Diluted EPS (TTM)
$-1.41
FCF margin
38.0%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$4.00
Gross profit per diluted share (TTM)
$3.91
Operating profit per diluted share (TTM)
$-1.14
EBITDA per diluted share (TTM)
$1.56
Net income per diluted share (TTM)
$-1.42
Operating cash flow per diluted share (TTM)
$1.59
Free cash flow per diluted share (TTM)
$1.59
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$0.85
Stock compensation per diluted share (TTM)
$0.28
Book value per share
$-0.56

Growth

11 metrics
Revenue growth YoY
+13.1%
Year over year
Net income growth YoY
+193.9%
Revenue (TTM)
$961.51M
Trailing 12 months
EPS growth YoY
+133.3%
Shares change YoY
+21.7%
Year over year · more shares
Revenue CAGR (3Y)
+47.8%
Revenue CAGR (5Y)
+117.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-60.8%
Debt / equity
—
Current ratio
2.7
EBITDA (TTM)
$342.38M
Free cash flow (TTM)
$365.85M
Quick ratio
2.6
Interest coverage
-3.8
Net debt / EBITDA
-0.8
Return on invested capital
—
Trailing 12 months
Net cash
−$20.61M
Latest balance sheet
Cash & equivalents
$96.97M
Total assets
$591.07M
Total debt
$395.61M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$367.49M
Capital expenditures (TTM)
$1.65M
R&D (TTM)
$211.37M
SG&A (TTM)
$321.49M
Stock compensation (TTM)
$68.76M
R&D / revenue
22.0%
Stock compensation / revenue
7.2%

Ownership (13F)

9 metrics
13F filers
320
13F filer change QoQ
+15
Institutional ownership
102.6%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+4.8%
Holder tenure
11.4
Price vs estimated holder cost
+25.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
20.5%

Short interest

3 metrics
Short interest
10.3%
Latest settlement · 5.8 days to cover
Days to cover
5.8d
Short-squeeze score
59 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 882796 CUSIP 09058V103 13F (30d) 129 filings 116 filers Visit website Investor relations